Medtronic: Potential For High Growth If They Execute


  • Medtronic’s diabetes business is expected to experience sustained growth with the introduction of the 780G system and the lifting of a warning letter in the U.S.
  • The company’s focus on innovation and expansion into growth markets, such as AFib, robotics, and structural heart, positions it for substantial future growth.
  • Medtronic has taken measures to enhance its supply chain resiliency and reduce costs, strengthening its global operations.

Life with diabetes. A girl walks through a waves in the sea. On the right arm is placed white sensor for continuous glucose monitoring in blood – CGM. A waterproof patch is glued over the sensor. Swimming with this type of sensor is possible

Dragoljub Bankovic/iStock via Getty Images

My grandfather who passed away a number of years ago was a good guy. Near the end of his life he suffered from Diabetes and had multiple strokes. I first learned about Medtronic (

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *